Viking TherapeuticsNASDAQ: VKTX

Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.

Viking Therapeutics stock is flying high thanks to its two leading pipeline candidates. But the biotech doesn't have any expected major catalysts to jolt its price by year-end.

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $47.39, denoting a -0.86% change from the preceding trading day.

Company's Receptor Co-Agonists Demonstrate Potent Body Weight Reductions, Decreased Food Intake and Improved Metabolic Profile in Healthy Rats and Diet-Induced Obese Mice SAN DIEGO , June 24, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced the presentation of preclinical data from a series of internally developed dual agonists of the amylin and calcitonin receptors at the 84th Scientific Sessions of the American Diabetes Association.  The presentation highlights the effects of treatment on body weight, food intake and metabolic profile in healthy rats and diet-induced obese (DIO) mice as compared to control cohorts treated with vehicle or the dual amylin and calcitonin receptor agonist cagrilintide.

In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $50.43, marking a -0.41% move from the previous day.

Viking Therapeutics has the potential to be a great growth stock. The company, however, faces a lot of competition in the GLP-1 drug market.

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $52.10, denoting a -0.69% change from the preceding trading day.

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Viking Therapeutics just reported (more) positive phase 2 clinical trial results. Though the company's shares dropped, interested investors shouldn't worry.